BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (March 2020)

18 slides from BioSpecifics Technologies's investor presentation, Mar 23, 2020

  1. Slide 1: Building a next-generation company on the foundation of our collagenase-based therapies

    Building a next-generation company on the foundation of our collagenase-based therapies MARCH 2020

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: CCH Commercial and Development Pipeline

    CCH Commercial and Development Pipeline Collagenases are naturally occurring enzymes responsible for the breakdown of collagen 3 Biopharmaceutical company that originated and continues to develop, in collaboration with Endo Pharmaceuticals, a specific collagenase formulation, collagenase clostridium

  4. Slide 4: Multiple Conditions Associated with Collagen Accumulation

    Multiple Conditions Associated with Collagen Accumulation Dupuytren’s contracturePeyronie’s disease 4 Approved indications, marketed as XIAFLEX Cellulite Filed for FDA approval Adhesive capsulitis (frozen shoulder)Plantar fibromatosisUterine fibroids Potential future indications include

  5. Slide 5: Profitable Company with Strong Balance Sheet to Support Future Growth Initiatives

    Profitable Company with Strong Balance Sheet to Support Future Growth Initiatives 5 Profitable with lean corporate structure and strong balance sheet ~$106M in cash as of 12/31/19 $11.8M 4Q19 royalties received from Endo sales of XIAFLEX 0 Debt Seeking to partner with companies that possess interest

  6. Slide 6: Diverse Development Pipeline

    Diverse Development Pipeline 6 Indication Preclinical Phase 1 Phase 2 Phase 3 Marketed APPROVED INDICATIONS Dupuytren’s Contracture Peyronie’s Disease FILED FOR APPROVAL Cellulite POTENTIAL FUTURE INDICATIONS Adhesive Capsulitis Uterine Fibroids Plantar Fibromatosis Source: Endo International plc

  7. Slide 7: Marketed XIAFLEX Indications

    Marketed XIAFLEX® Indications 7

  8. Slide 8: Peyronie's Disease

    Peyronie’s Disease 8 Can distort an erection and make sexual intercourse difficult or even impossible in advanced cases In some mild cases, the plaque can resolve spontaneously without medical interventionIn severe cases, the penis can be bent at a 90-degree angle during erection Characterized by pr

  9. Slide 9: Dupuytren's Contracture

    Dupuytren’s Contracture 9 Onset is characterized by the formation of nodules at the juncture between the fingers and palm that are composed primarily of collagenAs the disease progresses, collagen nodules begin to form a cord causing the patient’s finger(s) to contract, making it impossible to open

  10. Slide 10: CCH Development Pipeline

    CCH Development Pipeline $ biospecifics

  11. Slide 11: Cellulite

    Cellulite 11 Affects ~85-90% of post-pubertal femalesCurrently no FDA approved pharmaceutical products to address fibrous septae primarily composed of collagen Skin dimpling occurring mainly on the buttocks, thighs and lower abdomen and arms FDA StatusEndo announced BLA accepted for review by FDA in

  12. Slide 12: Adhesive Capsulitis

    Adhesive Capsulitis 12 Common available treatment options are often painful and can require anesthesiaLong-term intensive physical therapy, corticosteroids, manipulation under anesthesia and /or arthroscopic releaseCondition can last ~1 year to up to 3.5 years Inflammation and thickening of shoulder

  13. Slide 13: Plantar Fibromatosis

    Plantar Fibromatosis 13 Formation of nodules or cords along tendons of the footPatients often have Dupuytren’s disease, Peyronie’s disease and adhesive capsulitis Pain and disability caused by the thickening of the feet's deep connective tissue Market OpportunityAffects ~200,000 patients in the U.S.

  14. Slide 14: Uterine Fibroids

    Uterine Fibroids 14 Cause pelvic discomfort and pain, decreased fertility, pregnancy complications, increased rate of miscarriage, uterine bleeding, prolonged menstrual bleeding and frequent urinationLeading cause of hysterectomies in the U.S., accounting for ~250,000 hysterectomies and 30,000 myome

  15. Slide 15: BSTC Corporate Overview

    BSTC Corporate Overview $ biospecifics

  16. Slide 16: Profitable on an Ongoing Basis: Financial Highlights from 4Q19

    Profitable on an Ongoing Basis: Financial Highlights from 4Q19 16 For the twelve months ended 12/31/2019 12/31/2018 Cash and equivalents, and investments $105,808,125 $81,983,429 Income Statement Revenues $38,187,755 $32,961,443 Other income 1,986,596 1,398,599 Costs and expenses (9.875,703) (9,562,

  17. Slide 17: Corporate Outlook and Upcoming Milestones

    Corporate Outlook and Upcoming Milestones Continue to receive royalty revenues from partner Endo for both marketed XIAFLEX indications; Peyronie’s disease and Dupuytren’s contracture Endo expects 2020 full year revenue growth to be ~20%IP through 2028 17 Opportunistic about Business Development oppo

  18. Slide 18: Building a next-generation company on the foundation of our collagenase-based therapies

    Building a next-generation company on the foundation of our collagenase-based therapies MARCH 2020

Biospecifics Technologies — Investor Presentation (March 2020) on 6ix